Phase 2b RCT in 213 patients with cognitive impairment associated with schizophrenia: 24 weeks of adjunctive basmisanil 240 mg did not improve MCCB cognition vs placebo (primary analysis in 153), nor function or any stratified subgroup; it was well tolerated.
RCTn = 213 patients
Umbricht et al. A Phase 2b Multicenter Study to Evaluate Basmisanil as an Adjunctive Treatment in Patients With Cognitive Impairment Associated With Schizophrenia